BioNTech announced a collaboration with Gilead Sciences to test pumitamig combined with sacituzumab govitecan in a Phase 3 trial for PD-L1 low or negative triple-negative breast cancer (TNBC). This trial, ROSETTA Breast-01, will replace chemotherapy with sacituzumab govitecan to reflect the new standard of care. The combination aims to improve outcomes for this aggressive cancer type, which currently has limited treatment options and poor prognosis. Results could influence future treatment standards for metastatic TNBC patients.
BioNTech SE's ADR (BNTX) is trading at USD 90.79, down 0.55% as of Oct 22, 2026 18:02 WIB on Pluang. Gilead Sciences (GILD) shares are priced at USD 154.50 with a 0.61% gain at the same time. Gilead's market cap stands at $190.42 billion, reflecting its significant presence in the health sector amid this new clinical trial collaboration.
BioNTech SE will announce its financial results for the third quarter of 2026 on November 3, 2026, followed by a conference call and webcast for investors and the public. The company, known for its innovative cancer therapies and mRNA technology, wil...
BioNTech presented new Phase 2 clinical trial data at ESMO 2026 showing promising results for pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, combined with chemotherapy in treating advanced cancers including metastatic non-small cell lung cance...
